Sign up to save your podcasts
Or
Share 10X Genomics - The Story Behind the Single-Cell Revolution - $TXG
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
10X Genomics - The Story Behind the Single-Cell Revolution - $TXG
10X Genomics sprung from a simple but disruptive idea—stop averaging millions of cells and start listening to each one—and turned that insight into a platform (Chromium + Visium + Xenium) that rewired modern biology: fast microfluidics, barcode-laden gel beads, and user-friendly software made single-cell and spatial analysis scalable, drove thousands of high-impact papers, and powered a blockbuster IPO, even as bitter patent battles and the arrival of cheaper competitors forced the company into a fight for its future. Along the way 10X expanded beyond dissociated cells into spatial and in situ modalities, aimed at clinical-grade workflows, and doubled down on scale with GEM-X and partnerships like the Billion Cells Project to feed next-generation AI—yet the post-boom biotech winter, rising rivals such as Parse, and the pressure to lower per-cell costs have created a strategic crossroads: defend premium quality and clinical upside, or lean into commoditization to keep labs buying in. It’s a story of brilliant technical execution, platform economics, and hard-earned brand equity now being tested by market realities
---
- Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842
- Follow us on X @emportop
---
Transcript https://empor.top/us/TXG
- I. Introduction & Episode Roadmap
- II. The Genomics Revolution & Founding Context
- III. The Fluidigm Years & Birth of GemCode
- IV. Building the Platform: Chromium Launch (2015)
- V. The Single-Cell Biology Explosion (2016-2018)
- VI. Going Spatial: Visium & The Next Frontier (2018-2020)
- VII. IPO & Public Company Journey (2019-2021)
- VIII. The Great Reset & Strategic Inflection (2021-2023)
- IX. The Clinical & AI Pivot (2023-Present)
- X. The Business Model Deep-Dive
- XI. Porter's Five Forces Analysis
- XII. Hamilton's Seven Powers Analysis
- XIII. Strategic Crossroads & The Path Forward
- XIV. Playbook: Lessons for Founders & Investors
- XV. Epilogue & Current State
- XVI. Key Takeaways & Reflection
- XVII. Outro & Further Resources
View all episodes
By Empor.top10X Genomics sprung from a simple but disruptive idea—stop averaging millions of cells and start listening to each one—and turned that insight into a platform (Chromium + Visium + Xenium) that rewired modern biology: fast microfluidics, barcode-laden gel beads, and user-friendly software made single-cell and spatial analysis scalable, drove thousands of high-impact papers, and powered a blockbuster IPO, even as bitter patent battles and the arrival of cheaper competitors forced the company into a fight for its future. Along the way 10X expanded beyond dissociated cells into spatial and in situ modalities, aimed at clinical-grade workflows, and doubled down on scale with GEM-X and partnerships like the Billion Cells Project to feed next-generation AI—yet the post-boom biotech winter, rising rivals such as Parse, and the pressure to lower per-cell costs have created a strategic crossroads: defend premium quality and clinical upside, or lean into commoditization to keep labs buying in. It’s a story of brilliant technical execution, platform economics, and hard-earned brand equity now being tested by market realities
---
- Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842
- Follow us on X @emportop
---
Transcript https://empor.top/us/TXG
- I. Introduction & Episode Roadmap
- II. The Genomics Revolution & Founding Context
- III. The Fluidigm Years & Birth of GemCode
- IV. Building the Platform: Chromium Launch (2015)
- V. The Single-Cell Biology Explosion (2016-2018)
- VI. Going Spatial: Visium & The Next Frontier (2018-2020)
- VII. IPO & Public Company Journey (2019-2021)
- VIII. The Great Reset & Strategic Inflection (2021-2023)
- IX. The Clinical & AI Pivot (2023-Present)
- X. The Business Model Deep-Dive
- XI. Porter's Five Forces Analysis
- XII. Hamilton's Seven Powers Analysis
- XIII. Strategic Crossroads & The Path Forward
- XIV. Playbook: Lessons for Founders & Investors
- XV. Epilogue & Current State
- XVI. Key Takeaways & Reflection
- XVII. Outro & Further Resources